Article

ASCRS 2020: Assessing effectiveness of intracameral phenylephrine/ketorolac post-cataract surgery

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Denise Visco, MD, speaks with Ophthalmology Times Executive Editor David Hutton on the findings from her poster on the effects of intracameral phenylephrine/ketorolac 1.0%/0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia following cataract surgery, during the 2020 ASCRS virtual meeting.

 

See more ASCRS coverage content here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Related Content
Ophthalmologists present data on perfluorohexylactane eye drops
June 6th 2025

Ophthalmologists present data on perfluorohexylactane eye drops

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
May 18th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

EyePod: Transforming the MIGS pipeline into clinical practice
September 26th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
May 11th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
May 10th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

© 2025 MJH Life Sciences

All rights reserved.